Unknown OBSERVATIONAL NCT01050920

Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population

Sponsor: National University Hospital, Singapore

Conditions Cancer

Updated 6 times since 2017 Last updated: Jan 21, 2014 Started: Sep 30, 2013 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01050920, this observational or N/A phase trial focuses on Cancer and remains ongoing. Sponsored by National University Hospital, Singapore, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Jun 2018 — Jan 2021 [monthly]

Unknown Status
Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National University Hospital, Singapore

Data source: National University Hospital, Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore